Walgreens Stock Surges on Strategic Overhaul Announcement

Walgreens Boots Alliance shares experienced a dramatic upswing, climbing more than 12% following the release of quarterly earnings that surpassed market projections. The pharmacy chain, which has faced significant challenges, revealed a comprehensive restructuring plan that includes shuttering approximately 1,200 stores across the United States over the coming three years. This represents nearly 14% of the company’s domestic retail footprint.

Financial Performance Exceeds Projections

The company reported adjusted earnings of $0.39 per share for its fourth quarter of 2024, outperforming the $0.36 per share consensus among market analysts. Revenue reached $37.55 billion, substantially exceeding the $35.76 billion forecast by financial experts. Despite these positive indicators, Walgreens recorded a substantial net loss totaling $3 billion for the period.

Strategic Store Closures to Enhance Profitability

Chief Executive Officer Tim Wentworth outlined an aggressive store optimization strategy, targeting the closure of roughly 1,200 underperforming locations by 2027. The initial phase will see 500 stores shuttered during the 2025 fiscal year. Currently, only 75% of Walgreens’ 8,700 U.S. locations generate profits, positioning the remainder for potential elimination.

Wentworth emphasized that “this strategic transformation will require time, but we’re confident it will yield substantial financial benefits in the long term.” Management anticipates the closures will produce “immediate positive effects” on both profitability and free cash flow generation.

Key elements of the restructuring initiative include:

Should investors sell immediately? Or is it worth buying Walgreens?

• Concentrating resources on high-performing locations
• Adapting to evolving consumer behavior patterns
• Redeploying the majority of affected staff members
• Strengthening the remaining store infrastructure

Diverging Performance Across Business Segments

All three operational divisions demonstrated growth during the fourth quarter. The U.S. pharmacy segment generated $29.47 billion in revenue, representing a 6.5% increase and significantly surpassing the $28.09 billion projection. Pharmacy sales advanced by 9.6%, primarily driven by price increases for branded pharmaceuticals.

The retail sector presented a contrasting picture, with sales declining by 3.5%. While prescription volume grew by 1.7% to 302 million filled prescriptions, continued pressure from reduced reimbursement rates negatively impacted profit margins.

Cautious Outlook Amid Challenging Conditions

For fiscal year 2025, Walgreens provided adjusted earnings guidance between $1.40 and $1.80 per share, slightly below the $1.73 consensus estimate among market researchers. The company projects revenue in the range of $147 billion to $151 billion.

Despite the recent share price surge to $10.11, the equity remains under substantial pressure. Having been the worst-performing component in the S&P 500 this year, Walgreens had lost 65% of its value through Monday’s trading session. The stock continues to trade near historic lows, though investors appear increasingly receptive to the company’s turnaround narrative.